Breaking Finance News

A statement released earlier today by Wedbush about Ironwood Pharmaceuticals (NDAQ:IRWD) bumps the target price to $13.00

Yesterday Ironwood Pharmaceuticals (NDAQ:IRWD) traded 2.06% higher at $17.59. The company’s 50-day moving average is $15.49 and its 200-day moving average is $17.03. The last stock close price is up -6.98% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 876,853 shares of the stock were exchanged, down from an average trading volume of 1,216,430

Wedbush bumped up the target of Ironwood Pharmaceuticals (NDAQ:IRWD) to $13.00 indicating a possible downside of -0.26%.

Previously on 5/10/2017, Cowen reported about Ironwood Pharmaceuticals (NDAQ:IRWD) raised the target price from $0.00 to $20.00. At the time, this indicated a possible upside of 0.15%.

See Chart Below

Ironwood Pharmaceuticals (NDAQ:IRWD)

Ironwood Pharmaceuticals has a 52 week low of $12.48 and a 52 week high of $19.94 The company’s market cap is currently $0.

In addition to Wedbush reporting its target price, a total of 12 firms have issued a report on the stock. The consensus target price is $12.42 with 2 firms rating the stock a strong buy, 3 firms rating the stock a buy, 6 firms rating the stock a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell.

General Company Details For Ironwood Pharmaceuticals (NDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.